Asciminib is a Specifically Targeting the ABL Myristoyl Pocket (STAMP) inhibitor that has been approved for the treatment of CP CML in patients with prior exposure to at least two TKIs or the presence of the T315I mutation. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.